ClinicalTrials.gg
CompletedNCT01552902Updated Jun 10, 2021Results posted

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

A Phase 4 interventional study of Lisdexamfetamine dimesylate and Methylphenidate Hydrochloride in Attention-deficit/Hyperactivity Disorder, sponsored by Shire. Completed at 95 sites in 5 countries. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-10.

Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
549
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
Largest of 51
549 · median 48
Started
2012
with 2 others
Phase 4
23 of 51
none open now
Registered
33rd of 51
by date
Lead sponsor
18 of 51
Shire

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one has the largest enrollment, is one of 3 that started in 2012, is one of 23 in phase 4, and was the 33rd registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).

03

Conditions studied

  • Attention-deficit/Hyperactivity Disorder

Keywords

  • ADHD
04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be 13-17 years of age, inclusive, at the time of consent.
  • Subject must weigh more than 79.5lb.
  • The parent/LAR must be available at approximately 7:00AM (±2 hours) to dispense the dose of product for the study duration.
  • Subject, who is a female, must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test and a negative urine pregnancy test and agree to comply with any applicable requirements of the protocol.
  • Subject has an ADHD-RS-IV total score ≥28.
  • Subject is able to swallow a capsule.
  • Subject does not have hypertension and has a resting sitting blood pressure less than or equal to 135/85mmHg.

Exclusion criteria

Exclusion Criteria

  • Subject has a current, controlled (with medications prohibited in this study) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any significant comorbid Axis II disorder or significant Axis I disorder (such as post traumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, depressive or anxiety disorder.
  • Diagnosis of conduct disorder. Oppositional defiant disorder is not exclusionary.
  • Subject is considered a suicide risk, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded.
  • Subject is underweight or overweight.
  • Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition. Mild, stable asthma is not exclusionary.
  • Subject has a history of seizures (other than infantile febrile seizures), a chronic or current tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder.
  • Subject has a known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place him/her at increased vulnerability to the sympathomimetic effects of a stimulant medication.
  • Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
  • Subject has any or clinically significant laboratory abnormality.
  • Subject has current abnormal thyroid function, defined as abnormal thyroid stimulating hormone (TSH) and thyroxine (T4). Treatment with a stable dose of thyroid medication for at least 3 months is permitted.
  • Subject has a documented allergy, , or intolerance to amphetamine or to any in the product.
  • Subject has a documented allergy, hypersensitivity, or intolerance to MPH or to any excipients in the reference product.
  • Subject has failed to fully respond to an adequate course(s) (dose and duration) of MPH or amphetamine therapy.
  • Subject has a history of suspected substance abuse or dependence disorder (excluding nicotine). Subjects with a lifetime history of amphetamine, cocaine, or other stimulant abuse and/or dependence will be excluded.
  • Subject has a positive urine drug result.
  • Subject has previously participated in this study or another clinical study involving SPD489/NRP104.
  • Subject has glaucoma.
  • Subject is required to take or anticipates the need to take medications that have CNS effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are monoamine oxidase inhibitors. Stable use of bronchodilator inhalers is not exclusionary.
  • Subject is female and is pregnant or lactating.
  • Subject is well controlled on his/her current ADHD medication.
  • Subject has a pre-existing severe gastrointestinal tract narrowing.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
549 participants (actual)

Study arms

  • Experimental
    Lisdexamfetamine dimesylate

    Drug: Lisdexamfetamine dimesylate

  • Active comparator
    Methylphenidate Hydrochloride

    Drug: Methylphenidate Hydrochloride

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance

    Also known as: SPD489, Vyvanse, LDX

  • Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance

    Also known as: Concerta, OROS-MPH

  • DrugPlacebo

    Daily oral dosing in the AM for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at Week 6

    The ADHD-RS-IV was developed to measure the behaviors of children with ADHD and is commonly used in clinical studies of ADHD. The ADHD-RS-IV consisted of 18 items designed to reflect current symptomatology of ADHD based on Diagnostic and Statistical Manual of Mental Disorders, 4th Edition-Text Revision (DSM-IV-TR) criteria. Each item was scored on a 4-point scale ranging from 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54, Higher score = more severe symptoms.

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Percentage of Participants With an Improvement on Clinical Global Impression - Global Improvement (CGI-I) at Week 6

    The Clinical Global Impressions Scale permits a global evaluation of the participant's severity of illness and improvement over time. The scale included a severity of illness item and a global improvement item. The investigator performed the CGI-I to rate the improvement of a participant's ADHD symptoms based on a 7-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse.). Percentage of participants with an improved measurement (response of very much improved and much improved) is reported.

    Time frame: Week 6

Other outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were events between first dose of double-blind investigational product and up to 3 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline up to 3 days after last dose (last dose at Week 6)

  2. Change From Baseline in Blood Pressure at Week 6

    Time frame: Baseline, Week 6

  3. Change From Baseline in Pulse Rate at Week 6

    Time frame: Baseline, Week 6

07

Results

Posted Mar 18, 2015

Participant flow

The study was conducted at 77 sites in the United States, Canada, and Europe.

Participant flow — Overall Study
MilestonePlaceboLisdexamfetamine DimesylateMethylphenidate
Started110218219
Completed97181186
Not completed133733
Withdrew: Adverse event11514
Withdrew: Protocol violation333
Withdrew: Lack of efficacy431
Withdrew: Withdrawal by subject196
Withdrew: Lost to follow-up136
Withdrew: Other343

Outcome measures

PrimaryChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at Week 6

The ADHD-RS-IV was developed to measure the behaviors of children with ADHD and is commonly used in clinical studies of ADHD. The ADHD-RS-IV consisted of 18 items designed to reflect current symptomatology of ADHD based on Diagnostic and Statistical Manual of Mental Disorders, 4th Edition-Text Revision (DSM-IV-TR) criteria. Each item was scored on a 4-point scale ranging from 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54, Higher score = more severe symptoms.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at Week 6
units on a scalePlaceboLisdexamfetamine DimesylateMethylphenidate
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at Week 6-17 ± 1.03-25.4 ± 0.74-22.1 ± 0.73
Statistical analysis
  • Lisdexamfetamine Dimesylate vs Methylphenidate · Mixed Models Analysis · p = = 0.0013 · Difference in lsm: -3.4 · 95% CI -5.4 to -1.3
  • Placebo vs Lisdexamfetamine Dimesylate · Mixed Models Analysis · p = < 0.0001 · Difference in lsm: -8.5 · 95% CI -11 to -6
  • Placebo vs Methylphenidate · Mixed Models Analysis · p = < 0.0001 · Difference in lsm: -5.1 · 95% CI -7.6 to -2.6
SecondaryPercentage of Participants With an Improvement on Clinical Global Impression - Global Improvement (CGI-I) at Week 6

The Clinical Global Impressions Scale permits a global evaluation of the participant's severity of illness and improvement over time. The scale included a severity of illness item and a global improvement item. The investigator performed the CGI-I to rate the improvement of a participant's ADHD symptoms based on a 7-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse.). Percentage of participants with an improved measurement (response of very much improved and much improved) is reported.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With an Improvement on Clinical Global Impression - Global Improvement (CGI-I) at Week 6
percentage of participantsPlaceboLisdexamfetamine DimesylateMethylphenidate
Percentage of Participants With an Improvement on Clinical Global Impression - Global Improvement (CGI-I) at Week 65081.471.3
Other pre-specifiedNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were events between first dose of double-blind investigational product and up to 3 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline up to 3 days after last dose (last dose at Week 6)
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
participantsPlaceboLisdexamfetamine DimesylateMethylphenidate
Participants with TEAEs49145129
Participants with serious TEAEs111
Other pre-specifiedChange From Baseline in Blood Pressure at Week 6
Time frame:
Baseline, Week 6
Reported as:
Mean · millimeter of mercury (mmHg)
Change From Baseline in Blood Pressure at Week 6
millimeter of mercury (mmHg)PlaceboLisdexamfetamine DimesylateMethylphenidate
Systolic blood pressure-1 ± 9.881.5 ± 9.562.4 ± 9.97
Diastolic blood pressure-0.1 ± 8.13.4 ± 8.153.5 ± 8.59
Other pre-specifiedChange From Baseline in Pulse Rate at Week 6
Time frame:
Baseline, Week 6
Reported as:
Mean · Beats per minute
Change From Baseline in Pulse Rate at Week 6
Beats per minutePlaceboLisdexamfetamine DimesylateMethylphenidate
Change From Baseline in Pulse Rate at Week 62.4 ± 10.816.7 ± 12.468.2 ± 12.7

Adverse events

Collected over Baseline up to 3 days after last dose (last dose at Week 6). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/110 (0.9%)32/110 (29.1%)
Lisdexamfetamine Dimesylate—1/218 (0.5%)113/218 (51.8%)
Methylphenidate—1/219 (0.5%)99/219 (45.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboLisdexamfetamine DimesylateMethylphenidate
Psychotic episodePsychiatric disorders1/1100/2180/219
Suicidal ideationPsychiatric disorders0/1101/2180/219
AppendicitisInfections and infestations0/1100/2181/219
Most frequent other events
Most frequent other events
EventPlaceboLisdexamfetamine DimesylateMethylphenidate
Decreased appetiteMetabolism and nutrition disorders11/11069/21851/219
HeadacheNervous system disorders9/11033/21835/219
Weight decreasedInvestigations0/11023/21811/219
InsomniaPsychiatric disorders3/11017/21817/219
Dry mouthGastrointestinal disorders1/11016/2187/219
IrritabilityGeneral disorders7/11011/21815/219
DizzinessNervous system disorders0/11012/21811/219
NauseaGastrointestinal disorders3/11011/21811/219
Abdominal pain upperGastrointestinal disorders2/11011/2188/219

Baseline characteristics

The Safety set consisted of all participants in the Randomized set (all screened participants for whom a randomization number was generated) who took at least 1 dose of investigational product.

Age, Categorical
Age, Categorical(Participants)PlaceboLisdexamfetamine DimesylateMethylphenidateTotal
<=18 years110218219547
Between 18 and 65 years0000
>=65 years0000
Age, Continuous
Age, Continuous(years)PlaceboLisdexamfetamine DimesylateMethylphenidateTotal
Mean14.7 ± 1.3714.6 ± 1.3814.7 ± 1.4214.7 ± 1.40
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLisdexamfetamine DimesylateMethylphenidateTotal
Female348369186
Male76135150361
Attention-deficit/Hyperactivity Disorder (ADHD) Subtype
Attention-deficit/Hyperactivity Disorder (ADHD) Subtype(Participants)PlaceboLisdexamfetamine DimesylateMethylphenidateTotal
Predominantly Inattentive407071181
Predominantly Hyperactive/Impulsive2248
Combined Subtype68146144358
Clinical Global Impressions - Severity of Illness (CGI-S)
Clinical Global Impressions - Severity of Illness (CGI-S)(Participants)PlaceboLisdexamfetamine DimesylateMethylphenidateTotal
Borderline mentally ill1001
Mildly ill2417
Moderately ill6093115268
Markedly ill4110690237
Severely ill6151334
Attention-deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Total Score
Attention-deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Total Score(units on a scale)PlaceboLisdexamfetamine DimesylateMethylphenidateTotal
Mean36.1 ± 5.9137.2 ± 6.4636.9 ± 6.4236.9 ± 6.34
08

Study locations

95 sites
  • Harmonex Neuroscience Research, Inc.
    Dothan, Alabama 36303, United States
  • Center for Advanced Improvement
    Tucson, Arizona 85719, United States
  • Clinical Study Centers, LLC
    Little Rock, Arkansas 72211, United States
  • Shanti Clinical Trials
    Colton, California 92324, United States
  • Sun Valley Research Center
    Imperial, California 92251, United States
  • Synergy Clinical Research Center
    National City, California 91950, United States
  • Pacific Sleep Medicine, A Medical Corporation
    Oceanside, California 92054, United States
  • Neuropsychiatric Research Center for Orange County
    Orange, California 92868, United States
  • Peninsula Research Associates
    Rolling Hills Estates, California 90274, United States
  • PCSD - Feighner Research
    San Diego, California 92108, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • Elite Clinical Trials
    Wildomar, California 92595, United States
  • IMMUNOe International Research Center
    Centennial, Colorado 80112, United States
  • MCB Clinical Research Centers, LLC
    Colorado Springs, Colorado 80910, United States
  • Coastal Connecticut Research, LLC
    New London, Connecticut 06320, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34201, United States
  • Amedica Research Institute, Inc
    Hialeah, Florida 33013, United States
  • Clinical Neuroscience Solutions, Inc
    Jacksonville, Florida 32256, United States
  • Sarkis Clinical Trials
    Lake City, Florida 32055, United States
  • Florida Clinical Research Center, LLC
    Maitland, Florida 32751, United States
  • Prevention & Strengthening Solutions, Inc.
    Miami, Florida 33169, United States
  • Scientific Clinical Research, Inc.
    North Miami, Florida 33161, United States
  • Medical Research Group of Central Florida
    Orange City, Florida 32763, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806, United States
  • Compass Research, LLC
    Orlando, Florida 32806, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • Stedman Clinical Trials
    Tampa, Florida 33613, United States
  • Atlanta Institute of Medicine & Research, Inc
    Atlanta, Georgia 30328, United States
  • Clinical Research Center, University of Illinois at Chicago
    Chicago, Illinois 60608, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • Baber Research Group
    Naperville, Illinois 60563, United States
  • Pedia Research, LLC
    Newburgh, Indiana 47630, United States
  • Psychiatric Associates
    Overland Park, Kansas 66211, United States
  • Pedia Research, LLC
    Owensboro, Kentucky 42301, United States
  • Louisiana Resarch Associates, Inc.
    New Orleans, Louisiana 70114, United States
  • Marc Hertzman, MD, PC
    Rockville, Maryland 20852, United States
  • Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan 48307, United States
  • Clinical Neurophysiology Services, PC
    Sterling Heights, Michigan 48314, United States
  • Behavioral Medical Center - Troy
    Troy, Michigan 48083, United States
  • Comprehensive Psychiatric Associates
    Gladstone, Missouri 64118, United States
  • Psychiatric Care & Research Center
    O'Fallon, Missouri 63368, United States
  • St. Charles Psychiatric Associates - Midwest Research Group
    Saint Charles, Missouri 63301, United States
  • Premier Psychiatric Research Institute, LLC
    Lincoln, Nebraska 68526, United States
  • University of Nebraska Medical Center Dept Of Psychiatry
    Omaha, Nebraska 68198, United States
  • Center for Psychiatry & Behavioral Medicine, Inc.
    Las Vegas, Nevada 89128, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • The NeuroCognitive Institute
    Mount Arlington, New Jersey 07856, United States
  • Albuquerque Neuroscience, Inc.
    Albuquerque, New Mexico 87109, United States
  • Brain Resource Center
    New York, New York 10023, United States
  • Mount Sinai School of Medicine/Dept of Psychiaatry
    New York, New York 10029, United States
  • Duke University medical Center/ Duke ADHD Program
    Durham, North Carolina 27705, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • University of Cincinnati College of Medicine/UCPC
    Cincinnati, Ohio 45219, United States
  • The Ohio State University Nisonger Center
    Columbus, Ohio 43210, United States
  • Tulsa Clinical Research, LLC
    Tulsa, Oklahoma 74104, United States
  • Cyn3rgy Research
    Gresham, Oregon 97030, United States
  • Oregon Center for Clinical Investigations Inc
    Portland, Oregon 97210, United States
  • Summit Research Network
    Portland, Oregon 97210, United States
  • Oregon Center for Clinical Investigations, Inc
    Salem, Oregon 97301, United States
  • University Services
    West Chester, Pennsylvania 19380, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Rainbow Research, Inc.
    Barnwell, South Carolina 29812, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Research Across America/Psychiatric Medical Associates
    Dallas, Texas 75234, United States
  • Bayou City Research
    Houston, Texas 77007, United States
  • Claghorn-Lesem Research Clinic, Ltd.
    Houston, Texas 77008, United States
  • Clinical Trial Network
    Houston, Texas 77074, United States
  • Texas Center for Drug Development, Inc.
    Houston, Texas 77081, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77090, United States
  • Houston Clinical Trials, LLC
    Houston, Texas 77098, United States
  • Westex Clinical Investigations
    Lubbock, Texas 79423, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Univ of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • Ericksen Research and Development - Westside Medical
    Clinton, Utah 84015, United States
  • University of Virginia Child and Family Psychiatry Clinic
    Charlottesville, Virginia 22903, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Eastside Thereapeutic Resource
    Kirkland, Washington 98033, United States
  • Summit Research Network (Seattle), LLC
    Seattle, Washington 98104, United States
  • Rockwood Clinic, P.S.
    Spokane, Washington 99202, United States
  • True North Clinical Research
    Kentville, Nova Scotia B4N 4K9, Canada
  • The Kids Clinic
    Whitby, Ontario L1N 2L1, Canada
  • Schwerpunktpraxis fur Entwicklung und Lernen
    Bamberg, 96047, Germany
  • Klinik Fur Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie
    Frankfurt, 15236, Germany
  • Universitatsklinikum Freiburg
    Freiburg, 79104, Germany
  • Kinderarztpraxis Dr. Kaiser und Dr. MarineBe
    Hamburg, 22415, Germany
  • Zentralinstitut fur Seelische Gesundheit
    Mannheim, 68159, Germany
  • Medizinisches Studienzentrum Wurzburg
    Wurzburg, 97070, Germany
  • Vadaskert Gyermekpszichiatriai Korhaz es Szakambulancia
    Budapest, H-1021, Hungary
  • Bekes Megyei Pandy Kalman Korhaz
    Gyula, H-5700, Hungary
  • Pecsi Megyei Jogu varos Egyesitett Egeszsegugyi Intezmenyek
    Pecs, H-7632, Hungary
  • Szegedi Tudomanyegyetem
    Szeged, H-6725, Hungary
  • Gillbergcentrum
    Goteborg, 411 19, Sweden
  • PRIMA Barn-och Vuxenpsykiatri Jarva
    Spanga, 163 74, Sweden
09

References and documents

Publications

  • Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 2017 Nov;31(11):999-1014. doi: 10.1007/s40263-017-0468-2. PubMed 28980198 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2012 to primary completion in May 2014, 25 months.

Results were first posted in Mar 2015, 9 months after primary completion.

Of 62 phase 4 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2012
First posted
Mar 13, 2012
StartActual
Apr 3, 2012
Primary completionActual
May 22, 2014
CompletionActual
May 22, 2014
Results first posted
Mar 18, 2015
Last update
Jun 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01552902
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Mar 13, 2012
Start date
Apr 3, 2012
Primary completion
May 22, 2014
Completion
May 22, 2014
Results posted
Mar 18, 2015
Last update
Jun 10, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion